NASDAQ · PCSA
Processa Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PCSA: Nov 5, 2026
Processa Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-1.75.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks- Fintel · Oct 29, 6:42 PM EDTProcessa Pharmaceuticals, Inc. Appoints Dr. Sheila Gujrathi as Executive Chair and Announces FDA Clearance of Phase 2 IND for VT-7208Processa Pharmaceuticals, Inc. announced that on October 27, 2026, Justin Yorke resigned as chair of the board of directors, and on October 28, 2026, the board appointed Dr. Sheila Gujrathi as the non-employee executive chair of the board, effective immediately. Mr. Yorke will co
- RTTNews · Jul 31, 10:51 AM EDTWeekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals(RTTNews) – The healthcare sector delivered another eventful week, marked by major regulatory approvals, strategic partnerships, acquisitions, restructuring initiatives and significant clinical trial updates.
- RTTNews · Jul 29, 9:44 AM EDTProcessa Pharmaceuticals Acquires Vidya Therapeutics, Launch $200M Financing; Stock Down(RTTNews) – Processa Pharmaceuticals, Inc. (PCSA), a clinical-stage biotechnology company, has acquired privately held Vidya Therapeutics, Inc. and simultaneously raise approximately $200 million through a private financing.
- RTTNews · Jul 29, 9:44 AM EDTProcessa Pharmaceuticals To Acquire Vidya Therapeutics, Launch $200M Financing; Stock Down(RTTNews) – Processa Pharmaceuticals, Inc. (PCSA), a clinical-stage biotechnology company, announced it will acquire privately held Vidya Therapeutics, Inc. and simultaneously raise approximately $200 million through a private financing.
- RTTNews · Jun 11, 11:54 PM EDTTop Biotech Gainers: VRXA Begins A New Chapter, ADIL Opens Wallet, PGEN, PCSA On Watch…(RTTNews) – Today's top gainers were led by Australia-based Gelteq, which develops a novel ingestible gel-based drug delivery platform; Adial Pharmaceuticals, which announced the acquisition of Azora Therapeutics as part of its pipeline expansion strategy; Precigen, which is draw
- Fintel · Dec 21, 9:22 AM ESTProcessa Pharmaceuticals (PCSA) Price Target Increased by 2,400.00% to 25.50The average one-year price target for Processa Pharmaceuticals (NasdaqCM:PCSA) has been revised to $25.50 / share. This is an increase of 2,400.00% from the prior estimate of $1.02 dated December 3, 2025. The price target is an average of many targets provided
- RTTNews · Dec 20, 12:44 AM ESTWeekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO(RTTNews) – The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks.
- Zacks · Dec 18, 9:21 AM ESTPCSA Stock Soars on Upbeat Clinical Update From Breast Cancer StudyProcessa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.
- RTTNews · Dec 17, 9:54 AM ESTProcessa's NGC-Cap Shows Reduced Toxicity, Higher Metabolite Exposure In Breast Cancer Study(RTTNews) – Processa Pharmaceuticals, Inc. (PCSA) reported preliminary Phase 2 data showing that its lead oncology candidate, NGC-Cap, a combination of PCS6422 and capecitabine, significantly increased exposure to cancer-killing metabolites while maintaining comparable safety to
- RTTNews · Nov 23, 11:30 PM ESTButterfly Network, Citius Pharma Drive Biotech Momentum In After-Hours Trading(RTTNews) – Biotech and healthcare stocks saw notable activity in Friday's after-hours trading session, with several names posting sharp moves on the back of corporate updates and investor anticipation. Here are the highlights from November 21, 2025.
- RTTNews · Oct 8, 1:05 AM EDTBiotech Stocks Surge After Hours: PCSA, PALI, And QTTB Lead On Volume And Speculation(RTTNews) – Several small-cap biotech stocks posted sharp gains in after-hours trading on Tuesday, driven by speculative momentum, recent clinical updates, and capital market activity. Here's a look at the most notable movers, including Processa Pharmaceuticals, Palisade Bio, and
- RTTNews · Oct 7, 12:41 AM EDTTELO, PCSA, RVPH, NMTC, BRTX Jump In After-Hours Trading On Light News Flow And Select Updates(RTTNews) – Small-cap biotech stocks TELO, PCSA, RVPH, NMTC, and BRTX posted sharp after-hours gains on Monday, with moves driven by a mix of fresh company updates and speculative trading in the absence of new disclosures.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Processa Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.